| Exclusion Criteria: | 1) A. Cancer History - Grade 3b follicular lymphoma (according to the WHO classification) or histologic transformation from follicular lymphoma to aggressive lymphoma
2) Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of lymphoma progression at baseline (i.e., >/= 50% increase in the product of the longest perpendicular diameters of the lesion [greatest transverse diameter × perpendicular diameter] when compared with the nadir of lesion dimensions following radiotherapy and > 1.5 cm in the greatest transverse diameter)
3) Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1
4) Patients who received prior radio-immunotherapy for relapsed or refractory follicular NHL at least 1 year prior to first administration of study drug (i.e., rituximab) may participate if they meet minimal study requirements for peripheral blood counts (see below) and do not demonstrate evidence of myelodyplastic syndrome (MDS) on their screening bone marrow biopsy (as evidenced by cytogenetic or FISH criteria).
5) Concurrent systemic corticosteroid therapy (except low-dose corticosteroid therapy used to treat an illness other than lymphoma or single doses of up to 100 mg hydrocortisone, administered as prophylaxis against rituximab-mediated infusion reactions)
6) Other invasive malignancies within 3 years prior to first study drug administration (i.e., rituximab) except for adequately treated (with curative intent) basal or squamous cell skin cancer, in situ carcinoma of the cervix, in situ breast cancer, in situ prostate cancer, limited-stage bladder cancer, or other cancers from which the patient has been disease-free for at least 3 years.
7) History or evidence on physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, CNS lymphoma, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke)
8) Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL
9) B. General Medical Concerns - Current or recent (within the 28 days prior to Cycle 1, Day 1) participation in another experimental drug study
10) Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction within 1 year prior to Cycle 1, Day 1, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Cycle1, Day 1, or Grade II or greater peripheral vascular disease at study entry
11) Active infection requiring parenteral antibiotics on Cycle 1, Day 1
12) Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury within 28 days prior to Cycle 1, Day 1, or anticipation of need for major surgical procedure during the course of the study
13) Pregnancy (positive pregnancy test) or breast feeding
14) Serious, non-healing wound, ulcer, or bone fracture
15) Laboratory values: ANC < 1500/uL (may not be treated with G-CSF to maintain or exceed this level); Platelet count < 75,000/uL; Total bilirubin > 1.6 mg/dL; AST or ALT > 2.5 × the upper limit of normal (ULN); Serum creatinine > 2.0 mg/dL or measured creatinine clearance </= 50 mL/min; Hemoglobin < 9 g/dL (may not be transfused or treated with erythropoietin to maintain or exceed this level)
16) Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B surface antigen (HBsAg), hepatitis B IgG or IgM core antibody, or hepatitis C virus (HCV) antibody
17) History of other disease, metabolic dysfunction, physical finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications |